PubMed · 8046912
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
N V Bunchuk. 1993. [Rheumatic polymyalgia].. https://pubmed.ncbi.nlm.nih.gov/8046912/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
OBJECTIVE: Inconsistent effects of vitamin A supplementation on prevention of bronchopulmonary dysplasia have been reported. Meta-analysis of these reports resulted in a relative risk of 0.69-1.02 for death or bronchopulmonary dysplasia associated with vitamin A supplementation. Effective dosage regimens or serum retinol concentrations have not been determined in previous reports. The purpose of this pilot study was to define a vitamin A regimen that produces serum retinol concentrations of 25-55 micrograms/dl. STUDY DESIGN: In this three-phase study, 91 infants (mean birth weight 799-864 g) were enrolled. Vitamin A was administered three times/week for 4 weeks at an average daily dose of 986-2143 IU/day. Physical examinations were performed and serum retinol specimens were collected weekly to assess clinical signs of toxicity. RESULTS: The majority of serum retinol concentrations remained < 25 micrograms/dl until an intramuscular vitamin A dose of 5000 IU/dose three times/week was used. No clinical signs of toxicity were associated with the higher dosage and higher serum concentrations of vitamin A. CONCLUSION: A large clinical trial of vitamin A supplementation with 5000 IU/dose three times/week (25-114% more than the dose used in the three published clinical trials) is needed to assess whether vitamin A supplementation safely reduces the risk of bronchopulmonary dysplasia in very-low-birth-weight infants.
To determine whether activation of the type 2 adrenal steroid receptor affects granule cell death in the developing dentate gyrus, we treated rat pups with the type 2 receptor agonist RU28362 and examined degenerating cells using terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) and Nissl staining. RU28362 administration decreased the numbers of degenerating granule cells suggesting that type 2 receptor activation can rescue granule cells from degeneration.